110 related articles for article (PubMed ID: 20111903)
41. XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer.
Brewster AM; Alberg AJ; Strickland PT; Hoffman SC; Helzlsouer K
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1271-5. PubMed ID: 15298945
[TBL] [Abstract][Full Text] [Related]
42. XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects.
Yu KD; Chen AX; Qiu LX; Fan L; Yang C; Shao ZM
Breast Cancer Res Treat; 2010 Aug; 123(1):219-25. PubMed ID: 20127279
[TBL] [Abstract][Full Text] [Related]
43. Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects.
Yu KD; Di GH; Fan L; Chen AX; Yang C; Shao ZM
Breast Cancer Res Treat; 2010 Jul; 122(2):483-8. PubMed ID: 20043205
[TBL] [Abstract][Full Text] [Related]
44. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies.
Johnatty SE; Spurdle AB; Beesley J; Chen X; Hopper JL; Duffy DL; Chenevix-Trench G;
Breast Cancer Res Treat; 2008 May; 109(1):91-9. PubMed ID: 17592773
[TBL] [Abstract][Full Text] [Related]
45. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy.
Shen M; Hung RJ; Brennan P; Malaveille C; Donato F; Placidi D; Carta A; Hautefeuille A; Boffetta P; Porru S
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1234-40. PubMed ID: 14652287
[TBL] [Abstract][Full Text] [Related]
46. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis.
Li C; Jiang Z; Liu X
Mol Biol Rep; 2010 Jan; 37(1):301-9. PubMed ID: 19669592
[TBL] [Abstract][Full Text] [Related]
47. [Association between polymorphisms of XPD gene and susceptibility to chronic benzene poisoning].
Huang HL; Xu JN; Wang QK; Wang YW; Yang M; Chen Y; Li GL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Jul; 24(7):390-3. PubMed ID: 16889696
[TBL] [Abstract][Full Text] [Related]
48. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
[TBL] [Abstract][Full Text] [Related]
49. Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development.
Unal M; Güven M; Batar B; Ozaydin A; Sarici A; Devranoğlu K
Exp Eye Res; 2007 Sep; 85(3):328-34. PubMed ID: 17637462
[TBL] [Abstract][Full Text] [Related]
50. [Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing].
Xing DY; Qi J; Tan W; Miao XP; Liang G; Yu CY; Lu WF; Zhou CN; Wu M; Lin DX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb; 20(1):35-8. PubMed ID: 12579497
[TBL] [Abstract][Full Text] [Related]
51. X-ray repair cross-complementing group 4 (XRCC4) promoter -1394( *)T-related genotype, but not XRCC4 codon 247/intron 3 or xeroderma pigmentosum group D codon 312, 751/promoter -114, polymorphisms are correlated with higher susceptibility to myoma.
Hsieh YY; Chang CC; Bau DT; Yeh LS; Tsai FJ; Tsai CH
Fertil Steril; 2008 Oct; 90(4 Suppl):1417-23. PubMed ID: 18177646
[TBL] [Abstract][Full Text] [Related]
52. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
Liu G; Zhou W; Yeap BY; Su L; Wain JC; Poneros JM; Nishioka NS; Lynch TJ; Christiani DC
Carcinogenesis; 2007 Jun; 28(6):1254-8. PubMed ID: 17264068
[TBL] [Abstract][Full Text] [Related]
53. The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.
Yao L; Cao LH; Qiu LX; Yu L
Breast Cancer Res Treat; 2010 Sep; 123(2):577-80. PubMed ID: 20151320
[TBL] [Abstract][Full Text] [Related]
54. Current evidences on XPC polymorphisms and breast cancer susceptibility: a meta-analysis.
Zheng W; Cong XF; Cai WH; Yang S; Mao C; Zou HW
Breast Cancer Res Treat; 2011 Aug; 128(3):811-5. PubMed ID: 21318603
[TBL] [Abstract][Full Text] [Related]
55. The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk.
Yu KD; Chen AX; Yang C; Fan L; Huang AJ; Shao ZM
Breast Cancer Res Treat; 2012 Jan; 131(1):27-31. PubMed ID: 20737205
[TBL] [Abstract][Full Text] [Related]
56. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis.
Yuan W; Xu L; Chen W; Wang L; Fu Z; Pang D; Li D
Breast Cancer Res Treat; 2011 Jan; 125(2):467-72. PubMed ID: 20526805
[TBL] [Abstract][Full Text] [Related]
57. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
[TBL] [Abstract][Full Text] [Related]
58. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
59. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.
Zhou Q; Fu Y; Wen L; Deng Y; Chen J; Liu K
Technol Cancer Res Treat; 2021; 20():1533033821990046. PubMed ID: 33517857
[TBL] [Abstract][Full Text] [Related]
60. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.
Zhang J; Qiu LX; Leaw SJ; Hu XC; Chang JH
Med Oncol; 2011 Sep; 28(3):655-60. PubMed ID: 20354818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
